NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: A new candidate for treatment of neurodegenerative disorders

GLIA

Volumn 61, Issue 10, 2013, Pages 1724-1734

  Lee, Moonhee ^a   Mcgeer, Edith ^a   Kodela, Ravinder ^b   Kashfi, Khosrow ^b   Mcgeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer disease; IL 6; NO aspirin; NOSH aspirin; Parkinson disease; S aspirin; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; GLUTATHIONE; HYDROGEN SULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NBS 1120; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; CELL ACTIVATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INCUBATION TIME; MACROGLIA; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ALZHEIMER DISEASE; IL-6; NO-ASPIRIN; NOSH-ASPIRIN; PARKINSON DISEASE; S-ASPIRIN; TUMOR NECROSIS FACTOR-Α;

ANTI-INFLAMMATORY AGENTS; ASPIRIN; ASTROCYTES; ASTROCYTOMA; CELL LINE, TUMOR; CELLS, CULTURED; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICROGLIA; NF-KAPPA B; NITRATES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TEMPORAL LOBE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882866377     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22553     Document Type: Article

References (48)

1. Busija DW, Lacza Z, Rajapakse N, Shimizu K, Kis B, Bari F, Domoki F, Horiguchi T. 2004. Targeting mitochondrial ATP-sensitive potassium channels-A novel approach to neuroprotection. Brain Res Rev 46(3):282-294.
2. Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. 2010. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation. Cancer Lett 298:204-211.
3. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velazquez-Martinez CA, Boring D, Kashfi K. 2012b. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect. Biochemical Pharmacol 83:715-722.
4. Chattopadhyay M, Kodela R, Olson KR, Kashfi K. 2012a. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochemical and biophysical research communications 419:523-528.
5. Eto K, Ogasawara M, Umemura K, Nagai Y, Kimura H. 2002. Hydrogen sulfide is produced in response to neuronal excitation. J Neurosci 22:3386-3391.
6. Hashioka S, Klegeris A, Monji A, Kato T, Sawada M, McGeer PL, Kanba S. 2007. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 206:33-42.
7. Hattori Y, Kasai K, Gross SS. 2004. NO suppresses while peroxynitrite sustains NF-kappaB: A paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Cardiovasc Res 63:31-40.
8. Hauss-Wegrzyniak B, Vraniak P, Wenk GL.1999b. The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol Aging 20:305-313.
9. Hauss-Wegrzyniak B, Willard LB, Del Soldato P, Pepeu G, Wenk GL. 1999a. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res 815:36-43.
10. Hogaboam CM, Befus AD, Wallace JL. 1993. Modulation of rat mast cell reactivity by IL-1beta. Divergent effects on nitric oxide and platelet-activating factor release. J Immunol 151:3767-3774.
11. Hu LF, Wang S, Shi XR, Yao HH, Sun YH, Ding JH, Liu SY, Hu G. 2005. ATP-sensitive potassium channel opener iptakalim protected against the cytotoxicity of MPP+ on SH-SY5Y cells by decreasing extracellular glutamate level. J Neurochem 94:1570-1579.
12. Hu, LF, Wong, PT, Moore, PK, Bian, JS. 2007. Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 100:1121-1128.
13. Huang FP, Niedbala W, Wei XQ, Xu D, Feng GJ, Robinson JH, Lam C, Liew FY. 1998. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol 28:4062-4070.
14. Kashfi K, Olson KR. 2013. Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochemical Pharmacol 85:689-703.
15. Kashfi K, Rigas B. 2005. Molecular targets of nitric-oxide-donating aspirin in cancer. Biochem Soc Trans 33(Part 4):701-704.
16. Kimura Y, Kimura H. 2004 Hydrogen sulfide protects neurons from oxidative stress. Faseb J 18:1165-1167.
17. Klegeris A, Walker, DG, McGeer PL. 1999. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology 38:1017-1025.
18. Kodela R, Chattopadhyay M, Kashfi K. 2012. NOSH-aspirin: A novel nitric oxide-hydrogen sulfide-releasing hybrid: A new class of anti-inflammatory pharmaceuticals. ACS Med Chem Lett 3:257-262.
19. Lee M, Cho T, Jantaratnotai N, Wang YT, McGeer E, McGeer PL. 2010c. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. Faseb J 24:2533-2545.
20. Lee M, Kang Y, Suk K, Schwab C, Yu S, McGeer PL. 2011. Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein. J Biol Chem 286:41230-41245.
21. Lee M, McGeer E, McGeer PL. 2013. Neurotoxins released from interferon-gamma-stimulated human astrocytes. Neuroscience 229:164-175.
22. Lee M, Schwab C, Yu S, McGeer E, McGeer PL. 2009. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging 30:1523-1534.
23. Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL. 2010a. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. GLIA 58:103-113.
24. Lee M, Tazzari V, Giustarini D, Rossi R, Sparatore A, Del Soldato P, McGeer E, McGeer PL. 2010b. Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: Potential for treating Parkinson disease. J Biol Chem 285:17318-17328.
25. Lee SW, Hu YS, Hu LF, Lu Q, Dawe GS, Moore PK, Wong PT, Bian JS. 2006. Hydrogen sulphide regulates calcium homeostasis in microglial cells. GLIA 54:116-124.
26. Leschelle X, Goubern M, Andriamihaja M, Blottière HM, Couplan E, Gonzalez-Barroso MD, Petit C, Pagniez A, Chaumontet C, Mignotte B, Bouillaud F, Blachier F. 2005. Adaptative metabolic response of human colonic epithelial cells to the adverse effects of the luminal compound sulfide. Biochim Biophys Acta 1725: 201-212.
27. McGeer PL, McGeer EG. 2007. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28:639-647.
28. McGeer PL, McGeer EG. 2002. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 8:529-538.
29. McGeer PL, Schwab C, Parent A, Doudet D. 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann Neurol 54:599-604.
30. Módis K, Coletta C, Erdélyi K, Papapetropoulos A, Szabo C. 2013. Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. Faseb J 27:601-611.
31. Nagai Y, Tsugane M, Oka J, Kimura H. 2004. Hydrogen sulfide induces calcium waves in astrocytes. Faseb J 18:557-559.
32. Naseem KM. 2005. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 26:33-65.
33. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. 1997. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347-1365.
34. Qu K, Chen CP, Halliwell B, Moore PK, Wong PT. 2006. Hydrogen sulfide is a mediator of cerebral ischemic damage. Stroke 37:889-893.
35. Qu K, Lee SW, Bian JS, Low CM, Wong PT. 2008. Hydrogen sulfide: Neurochemistry and neurobiology. Neurochem Int 52:155-165.
36. Reiffenstein RJ, Hulbert WC, Roth SH. 1992. Toxicology of hydrogen sulfide. Annu Rev Pharmacol Toxicol 32:109-134.
37. Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM. 2003. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem 278:391-399.
38. Stuehr DJ. 1997. Structure-function aspects in the nitric oxide synthases. Annual Rev Pharmacol Toxicol 37:339-359.
39. Szabó C. 2007. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6:917-935.
40. Van Wagoner NJ, Benveniste EN. 1999. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol 100:124-139.
41. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. 2007. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836-1842.
42. 2S be the third endogenous gaseous transmitter? Faseb J 16:1792-1798.
43. Wenk GL, McGann K, Mencarelli A, Hauss-Wegrzyniak B, Del Soldato P, Fiorucci S. 2000. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur J Pharmacol 402(1-2):77-85.
44. Wenk GL, Rosi S, McGann K, Hauss-Wegrzyniak B. 2002. A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Eur J Pharmacol 453(2-3):319-324.
45. Whitton PS. 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150:963-976.
46. Yamada K, Inagaki N. 2005. Neuroprotection by KATP channels. J Mol Cell Cardiol 38:945-949.
47. +-induced degeneration of dopaminergic neurons in association with astrocyte activation. Int J Neuropsychopharmacol 13:1-11.
48. ATP channel opener. EMBO J 20:6008-6016.